Review Article
A Systematic Review and Meta-Analysis of the Efficacy and Safety of Rasagiline or Pramipexole in the Treatment of Early Parkinson’s Disease
Table 1
The main characteristics of the rasagiline studies included in the systematic review.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Values are reported as mean ± standard deviation. CD = carbidopa, DAA = dopamine agonists, EC = entacapone, mo = months, PBO = placebo, PD = Parkinson’s disease, PPX = pramipexole, RA = rasagiline, RCT = randomized controlled trial, RG = rotigotine, RR = ropinirole, AC = anticholinergics, AM = amantadine, COMT-I = Catechol-O-methyl transferase inhibitors, LD = levodopa, MAOB-I = monoamine oxidase B inhibitors, wk = weeks, yr = years, and H&Y stage = Hoehn and Yahr stage. aWithdrawals were due to noncompliance. bRasagiline as add-on therapy to dopamine agonists in patients with early PD. cPost hoc analysis of the ADAGIO study [24]. dDelayed-start rasagiline 1 mg and 2 mg groups are combined as one because the treatment was in both placebo and we extracted data from week 36. eWithdrawals reported before starting active treatment at 36 weeks. fOne patient was reported as having a disease duration of 10 years. g94% of study subjects had a Hoehn and Yahr stage of ≤2. |